By Sherri Oslick —

About
Court Report:  Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.

Aventis Pharma S.A. et al. v. Sun Pharmaceutical Industries Ltd.
et al.
3:09-cv-04333; filed August 24, 2009 in the
District Court of New Jersey

• Plaintiffs:  Aventis Pharma S.A.; Sanofi-Aventis
U.S. LLC
• Defendants:  Sun Pharmaceutical Industries Ltd.;
Sun Pharmaceutical Industries Inc.; Sun Pharma Global FZE; Caraco
Pharmaceutical Laboratories, Ltd.

Aventis Pharma S.A. et al. v. Sun Pharmaceutical Industries Ltd.
et al.
1:09-cv-00630; filed August 21, 2009 in the
District Court of Delaware

• Plaintiffs:  Aventis Pharma S.A.; Sanofi-Aventis
US LLC
• Defendants:  Sun Pharmaceutical Industries Ltd.;
Sun Pharmaceutical Industries Inc.; Sun Pharma Global FZE; Caraco
Pharmaceutical Laboratories Ltd.

The complaints in these cases are substantially
identical.  Infringement of U.S.
Patent Nos. 5,714,512 ("Compositions Containing Taxane Derivatives,"
issued February 3, 1998) and 5,750,561 (same title, issued May 12, 1998)
following a Paragraph IV certification as part of Sun's filing of an NDA (under
§ 505(b)(2) of the Food, Drug and Cosmetic Act) to manufacture a generic
version of Aventis' Taxotere® (docetaxel, used to treat breast, lung, prostate,
gastric, and head and neck cancers).  View the Delaware complaint here.

LadaTech LLC v. Illumina Inc.
1:09-cv-00627; filed August 21, 2009 in the
District Court of Delaware

Infringement of U.S. Patent No. 6,107,023 ("DNA
Amplification and Subtraction Techniques," issued August 22, 2000) based on
Illumina's manufacture and sale of products and associated instrumentation for
use in Illumina's Genome Analyzer System.  View the complaint here.

Eli Lilly and Co. v. Anchen Pharmaceuticals, Inc. et al.
1:09-cv-01029; filed August 20, 2009 in the
Southern District of Indiana

• Plaintiff:  Eli Lilly and Company
• Defendants:  Anchen Pharmaceuticals, Inc.; Anchen,
Inc.

Infringement of U.S. Patent No. 5,023,269 ("3-Aryloxy-3-Substituted
Propanamines," issued June 11, 1991) following a Paragraph IV
certification as part of Anchen's filing of an ANDA to manufacture a generic
version of Lilly's Cymbalta® (duloxetine hydrochloride, used to treat
depression and generalized anxiety disorder and for the management of diabetic
peripheral neuropathic pain and fibromyalgia).  View the complaint here.